Smart Inhalers Market by Product (Inhalers and Nebulizers), Indication (Asthma and COPD), and Distribution Channel (Hospital Pharmacies and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021–2030
The global smart inhalers market was valued at $118 million in 2020, and is estimated to reach $1,113.57 million by 2030, growing at a CAGR of 25.1% from 2021 to 2030.
Smart inhalers are devices used for delivering a variety of medication through inhalation and can be connected to devices such as smartphones or any digital device. The drugs used in the inhalers include, anti-cholinergic, glucocorticoids, insulin, and beta-agonists for the treatment and prevention of respiratory diseases, such as asthma and chronic obstructive pulmonary diseases (COPD). Smart inhalers have sensors that send feeds back, reminders and monitors an individual’s health regularly. It also notifies about high pollution areas as well high pollen threat.
Smart inhalers have proved to increase the adherence rate in patients suffering from asthma and COPD. Moreover, smart inhalers also help to monitor the technique used for inhaling the medicine in an effective manner as compared to normal inhalers. Smart Inhalers are of two types, namely metered dose inhalers and dry powder inhalers.
This market is majorly driven by increase in population suffering from asthma and COPD. Increase in air pollution directly increases asthma and other respiratory cases, which in turn, boosts the demand for smart monitoring devices. According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, causing 3.23 million deaths in 2019 and more than 80% of these deaths occurred in low and middle income countries. Thus, such large mortality and unmet medical demands can be reduced by increased initiatives and utilization of smart inhalers and is an opportunity for the investors to invest in such countries.
For instance, in July 2020, Novartis International AG, one of the leading players received European Commission’s (EC) approval for Enerzair Breezhaler, the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the European Union. It was developed in collaboration with Propeller Health’s app and sensor custom-built for the Breezhaler device. Thus, launch of such products and collaborations among the key market players further boost the market growth.
Market players have invested in various developing smart inhalers products that aid in monitoring asthma and COPD, wherein, the data acquired by the sensors of these smart inhalers is shared with the patient and healthcare professionals to track their inhaler usage. The data monitored is then shared using the Bluetooth technology to their mobile apps through an online platform and subsequently, electronic health records (EHR) or electronic medical records (EMR) are maintained.
Smart inhalers are expected to increase the adherence rate of patients to traditional inhalers. Unintended non-adherence arises when patients misunderstand instructions and forget or have physical problems such as poor coordination or eyesight, thus leading to limited ability to take their medicines. Smart inhalers, such as the Adherium’s Hailie solution is a cloud-based platform, which captures medication use data from Bluetooth enabled sensors that wraps around patient inhalers and provides real-time feedback to patients via the Hailie app and to their physicians via the Hailie portal. Increase in non-adherence is known to be a source of disease to patients as well as financial burden to payers and prescribers. Thus, increase in adherence to smart inhalers is expected to improve the treatment of asthma and COPD patients.
However, as smart inhalers are wirelessly connected and keep a record of the patient’s data, the risk of data leakage and misuse of data increases significantly. As smart inhaler is a new device, its acceptance among patients as well as physicians is considerably low and is thus, expected to restrain the growth of the market. Furthermore, presence of a plethora of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities for market growth during the forecast period.
The smart inhalers market is segmented into product, indication, distribution channel, and region. On the basis of product, the market is segmented into inhalers and nebulizers. The inhalers are further bifurcated dry powdered inhalers (DPIs) and metered dose inhalers (MDI's) . On the basis of indication, the market is segmented into asthma and COPD. On the basis of distribution channel, the market is bifurcated in to hospital pharmacies and retail pharmacies.
Region wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, Middle East, and Africa (LAMEA).
The major players profiled in the report are Adherium Limited, Aptar Group Inc. (Cohero Health Inc.), AstraZeneca, Inc., Cognita Labs, Llc., GlaxoSmithKline Plc, Novartis AG, OPKO Health Inc., Philip Morris International Inc. (Vectura Group Plc), ResMed Inc. (Propeller Health) and Teva Pharmaceutical Industries Ltd.
KEY BENEFITS FOR STAKEHOLDERS
This report provides an extensive analysis of the current and emerging market trends and dynamics in the global smart inhalers market to identify the prevailing opportunities.
This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Region- & country-wise analysis is provided to understand the market trends and dynamics.
KEY MARKET SEGMENTS
By Product
Inhalers
Dry Powdered Inhalers (DPIs)
Metered Dose Inhalers (MDI's)
Nebulizers
By Indication
Asthma
COPD
By Distribution Channel
Hospitals Pharmacies
Retail Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Russia
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
UAE
Turkey
Saudi Arabia
Rest of LAMEA
KEY MARKET PLAYERS
Adherium Limited
Aptar Group Inc. (Cohero Health Inc.)
AstraZeneca, Inc.
Cognita Labs, LLC
GlaxoSmithKline Plc
Novartis AG
OPKO Health Inc.
Philip Morris International Inc. (Vectura Group Plc)
Resmed Inc. (Propeller Health)
Teva Pharmaceutical Industries Ltd.
- CHAPTER 1: INTRODUCTION
- 1.1.Report Description
- 1.2.Key Market Segments
- 1.3.Key Benefits
- 1.4.Research Methodology
- 1.4.1.Primary Research
- 1.4.2.Secondary Research
- 1.4.3.Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1.CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1.Market Definition and Scope
- 3.2.Key Findings
- 3.2.1.Top Investment Pockets
- 3.2.2.Top Winning Strategies
- 3.3.Porter's Five Forces Analysis
- 3.3.1.Bargaining Power of Suppliers
- 3.3.2.Threat of New Entrants
- 3.3.3.Threat of Substitutes
- 3.3.4.Competitive Rivalry
- 3.3.5.Bargaining Power among Buyers
- 3.4.Market Share Analysis/Top Player Positioning
- 3.4.1.Market Share Analysis/Top Player Positioning 2020
- 3.5.Market Dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6. COVID-19 Impact Analysis
- CHAPTER 4: SMART INHALERS MARKET, BY PRODUCT
- 4.1.Market Overview
- 4.1.1Market Size and Forecast, By Product
- 4.2.Inhalers
- 4.2.1.Key Market Trends, Growth Factors and Opportunities
- 4.2.2.Market Size and Forecast, By Region
- 4.2.3.Market Share Analysis, By Country
- 4.2.4.Dry Powdered Inhalers (DPIs)
- 4.2.4.1.Market Size and Forecast
- 4.2.5.Metered Dose Inhalers (MDIs)
- 4.2.5.1.Market Size and Forecast
- 4.3.Nebulizers
- 4.3.1.Key Market Trends, Growth Factors and Opportunities
- 4.3.2.Market Size and Forecast, By Region
- 4.3.3.Market Share Analysis, By Country
- CHAPTER 5: SMART INHALERS MARKET, BY INDICATION
- 5.1.Market Overview
- 5.1.1Market Size and Forecast, By Indication
- 5.2.Asthma
- 5.2.1.Market Size and Forecast, By Region
- 5.2.2.Market Share Analysis, By Country
- 5.3.COPD
- 5.3.1.Market Size and Forecast, By Region
- 5.3.2.Market Share Analysis, By Country
- CHAPTER 6: SMART INHALERS MARKET, BY END USER
- 6.1.Market Overview
- 6.1.1Market Size and Forecast, By End User
- 6.2.Hospital Pharmacies
- 6.2.1.Market Size and Forecast, By Region
- 6.2.2.Market Share Analysis, By Country
- 6.3.Retail Pharmacies
- 6.3.1.Market Size and Forecast, By Region
- 6.3.2.Market Share Analysis, By Country
- CHAPTER 7: SMART INHALERS MARKET, BY REGION
- 7.1.Market Overview
- 7.1.1Market Size and Forecast, By Region
- 7.2.North America
- 7.2.1.Key Market Trends and Opportunities
- 7.2.2.Market Size and Forecast, By Product
- 7.2.3.Market Size and Forecast, By Indication
- 7.2.4.Market Size and Forecast, By End User
- 7.2.5.Market Size and Forecast, By Country
- 7.2.6.United States Smart Inhalers Market
- 7.2.6.1.Market Size and Forecast, By Product
- 7.2.6.2.Market Size and Forecast, By Indication
- 7.2.6.3.Market Size and Forecast, By End User
- 7.2.7.Canada Smart Inhalers Market
- 7.2.7.1.Market Size and Forecast, By Product
- 7.2.7.2.Market Size and Forecast, By Indication
- 7.2.7.3.Market Size and Forecast, By End User
- 7.2.8.Mexico Smart Inhalers Market
- 7.2.8.1.Market Size and Forecast, By Product
- 7.2.8.2.Market Size and Forecast, By Indication
- 7.2.8.3.Market Size and Forecast, By End User
- 7.3.Europe
- 7.3.1.Key Market Trends and Opportunities
- 7.3.2.Market Size and Forecast, By Product
- 7.3.3.Market Size and Forecast, By Indication
- 7.3.4.Market Size and Forecast, By End User
- 7.3.5.Market Size and Forecast, By Country
- 7.3.6.France Smart Inhalers Market
- 7.3.6.1.Market Size and Forecast, By Product
- 7.3.6.2.Market Size and Forecast, By Indication
- 7.3.6.3.Market Size and Forecast, By End User
- 7.3.7.Germany Smart Inhalers Market
- 7.3.7.1.Market Size and Forecast, By Product
- 7.3.7.2.Market Size and Forecast, By Indication
- 7.3.7.3.Market Size and Forecast, By End User
- 7.3.8.Italy Smart Inhalers Market
- 7.3.8.1.Market Size and Forecast, By Product
- 7.3.8.2.Market Size and Forecast, By Indication
- 7.3.8.3.Market Size and Forecast, By End User
- 7.3.9.U.K Smart Inhalers Market
- 7.3.9.1.Market Size and Forecast, By Product
- 7.3.9.2.Market Size and Forecast, By Indication
- 7.3.9.3.Market Size and Forecast, By End User
- 7.3.10.Russia Smart Inhalers Market
- 7.3.10.1.Market Size and Forecast, By Product
- 7.3.10.2.Market Size and Forecast, By Indication
- 7.3.10.3.Market Size and Forecast, By End User
- 7.3.11.Rest Of Europe Smart Inhalers Market
- 7.3.11.1.Market Size and Forecast, By Product
- 7.3.11.2.Market Size and Forecast, By Indication
- 7.3.11.3.Market Size and Forecast, By End User
- 7.4.Asia-Pacific
- 7.4.1.Key Market Trends and Opportunities
- 7.4.2.Market Size and Forecast, By Product
- 7.4.3.Market Size and Forecast, By Indication
- 7.4.4.Market Size and Forecast, By End User
- 7.4.5.Market Size and Forecast, By Country
- 7.4.6.China Smart Inhalers Market
- 7.4.6.1.Market Size and Forecast, By Product
- 7.4.6.2.Market Size and Forecast, By Indication
- 7.4.6.3.Market Size and Forecast, By End User
- 7.4.7.Japan Smart Inhalers Market
- 7.4.7.1.Market Size and Forecast, By Product
- 7.4.7.2.Market Size and Forecast, By Indication
- 7.4.7.3.Market Size and Forecast, By End User
- 7.4.8.India Smart Inhalers Market
- 7.4.8.1.Market Size and Forecast, By Product
- 7.4.8.2.Market Size and Forecast, By Indication
- 7.4.8.3.Market Size and Forecast, By End User
- 7.4.9.Australia Smart Inhalers Market
- 7.4.9.1.Market Size and Forecast, By Product
- 7.4.9.2.Market Size and Forecast, By Indication
- 7.4.9.3.Market Size and Forecast, By End User
- 7.4.10.Rest of Asia Pacific Smart Inhalers Market
- 7.4.10.1.Market Size and Forecast, By Product
- 7.4.10.2.Market Size and Forecast, By Indication
- 7.4.10.3.Market Size and Forecast, By End User
- 7.5.LAMEA
- 7.5.1.Key Market Trends and Opportunities
- 7.5.2.Market Size and Forecast, By Product
- 7.5.3.Market Size and Forecast, By Indication
- 7.5.4.Market Size and Forecast, By End User
- 7.5.5.Market Size and Forecast, By Country
- 7.5.6.Brazil Smart Inhalers Market
- 7.5.6.1.Market Size and Forecast, By Product
- 7.5.6.2.Market Size and Forecast, By Indication
- 7.5.6.3.Market Size and Forecast, By End User
- 7.5.7.Saudi Arabia Smart Inhalers Market
- 7.5.7.1.Market Size and Forecast, By Product
- 7.5.7.2.Market Size and Forecast, By Indication
- 7.5.7.3.Market Size and Forecast, By End User
- 7.5.8.UAE Smart Inhalers Market
- 7.5.8.1.Market Size and Forecast, By Product
- 7.5.8.2.Market Size and Forecast, By Indication
- 7.5.8.3.Market Size and Forecast, By End User
- 7.5.9.Turkey Smart Inhalers Market
- 7.5.9.1.Market Size and Forecast, By Product
- 7.5.9.2.Market Size and Forecast, By Indication
- 7.5.9.3.Market Size and Forecast, By End User
- 7.5.10.Rest of LAMEA Smart Inhalers Market
- 7.5.10.1.Market Size and Forecast, By Product
- 7.5.10.2.Market Size and Forecast, By Indication
- 7.5.10.3.Market Size and Forecast, By End User
- CHAPTER 8: COMPANY PROFILES
- 8.1.Adherium Limited
- 8.1.1.Company Overview
- 8.1.2.Key Executives
- 8.1.3.Company snapshot
- 8.1.4.Operating business segments
- 8.1.5.Product portfolio
- 8.1.6.Business Performance
- 8.1.7.Key Strategic Moves and Developments
- 8.2.Aptar Group Inc. (Cohero Health Inc.)
- 8.2.1.Company Overview
- 8.2.2.Key Executives
- 8.2.3.Company snapshot
- 8.2.4.Operating business segments
- 8.2.5.Product portfolio
- 8.2.6.Business Performance
- 8.2.7.Key Strategic Moves and Developments
- 8.3.AstraZeneca, Inc.
- 8.3.1.Company Overview
- 8.3.2.Key Executives
- 8.3.3.Company snapshot
- 8.3.4.Operating business segments
- 8.3.5.Product portfolio
- 8.3.6.Business Performance
- 8.3.7.Key Strategic Moves and Developments
- 8.4.Cognita Labs, LLC
- 8.4.1.Company Overview
- 8.4.2.Key Executives
- 8.4.3.Company snapshot
- 8.4.4.Operating business segments
- 8.4.5.Product portfolio
- 8.4.6.Key Strategic Moves and Developments
- 8.5.GlaxoSmithKline Plc
- 8.5.1.Company Overview
- 8.5.2.Key Executives
- 8.5.3.Company snapshot
- 8.5.4.Operating business segments
- 8.5.5.Product portfolio
- 8.5.6.Business Performance
- 8.6.Novartis AG
- 8.6.1.Company Overview
- 8.6.2.Key Executives
- 8.6.3.Company snapshot
- 8.6.4.Operating business segments
- 8.6.5.Product portfolio
- 8.6.6.Business Performance
- 8.6.7.Key Strategic Moves and Developments
- 8.7.OPKO Health Inc.
- 8.7.1.Company Overview
- 8.7.2.Key Executives
- 8.7.3.Company snapshot
- 8.7.4.Operating business segments
- 8.7.5.Product portfolio
- 8.7.6.Business Performance
- 8.8.Philip Morris International Inc. (Vectura Group Plc)
- 8.8.1.Company Overview
- 8.8.2.Key Executives
- 8.8.3.Company snapshot
- 8.8.4.Operating business segments
- 8.8.5.Product portfolio
- 8.8.6.Business Performance
- 8.8.7.Key Strategic Moves and Developments
- 8.9.Resmed Inc. (Propeller Health)
- 8.9.1.Company Overview
- 8.9.2.Key Executives
- 8.9.3.Company snapshot
- 8.9.4.Operating business segments
- 8.9.5.Product portfolio
- 8.9.6.Business Performance
- 8.9.7.Key Strategic Moves and Developments
- 8.10.Teva Pharmaceutical Industries Ltd.
- 8.10.1.Company Overview
- 8.10.2.Key Executives
- 8.10.3.Company snapshot
- 8.10.4.Operating business segments
- 8.10.5.Product portfolio
- 8.10.6.Business Performance
- 8.10.7.Key Strategic Moves and Developments
- LIST OF TABLES
- TABLE 1.GLOBAL SMART INHALERS MARKET, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 2.GLOBAL SMART INHALERS MARKET FOR INHALERS, BY REGION, 2020-2030 ($MILLION)
- TABLE 3.GLOBAL SMART INHALERS MARKET FOR NEBULIZERS, BY REGION, 2020-2030 ($MILLION)
- TABLE 4.GLOBAL SMART INHALERS MARKET, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 5.GLOBAL SMART INHALERS MARKET FOR ASTHMA, BY REGION, 2020-2030 ($MILLION)
- TABLE 6.GLOBAL SMART INHALERS MARKET FOR COPD, BY REGION, 2020-2030 ($MILLION)
- TABLE 7.GLOBAL SMART INHALERS MARKET, BY END USER, 2020-2030 ($MILLION)
- TABLE 8.GLOBAL SMART INHALERS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2020-2030 ($MILLION)
- TABLE 9.GLOBAL SMART INHALERS MARKET FOR RETAIL PHARMACIES, BY REGION, 2020-2030 ($MILLION)
- TABLE 10.GLOBAL SMART INHALERS MARKET, BY REGION, 2020-2030 ($MILLION)
- TABLE 11.NORTH AMERICA SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 12.NORTH AMERICA SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 13.NORTH AMERICA SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 14.UNITED STATES SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 15.UNITED STATES SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 16.UNITED STATES SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 17.CANADA SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 18.CANADA SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 19.CANADA SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 20.MEXICO SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 21.MEXICO SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 22.MEXICO SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 23.EUROPE SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 24.EUROPE SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 25.EUROPE SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 26.FRANCE SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 27.FRANCE SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 28.FRANCE SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 29.GERMANY SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 30.GERMANY SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 31.GERMANY SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 32.ITALY SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 33.ITALY SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 34.ITALY SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 35.UNITED KINGDOM SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 36.UNITED KINGDOM SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 37.UNITED KINGDOM SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 38.RUSSIA SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 39.RUSSIA SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 40.RUSSIA SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 41.REST OF EUROPE SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 42.REST OF EUROPE SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 43.REST OF EUROPE SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 44.ASIA-PACIFIC SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 45.ASIA-PACIFIC SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 46.ASIA-PACIFIC SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 47.CHINA SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 48.CHINA SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 49.CHINA SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 50.JAPAN SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 51.JAPAN SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 52.JAPAN SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 53.INDIA SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 54.INDIA SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 55.INDIA SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 56.AUSTRALIA SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 57.AUSTRALIA SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 58.AUSTRALIA SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 59.REST OF ASIA PACIFIC SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 60.REST OF ASIA PACIFIC SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 61.REST OF ASIA PACIFIC SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 62.LAMEA SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 63.LAMEA SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 64.LAMEA SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 65.BRAZIL SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 66.BRAZIL SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 67.BRAZIL SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 68.SAUDI ARABIA SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 69.SAUDI ARABIA SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 70.SAUDI ARABIA SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 71.UAE SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 72.UAE SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 73.UAE SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 74.TURKEY SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 75.TURKEY SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 76.TURKEY SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 77.REST OF LAMEA SMART INHALERS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 78.REST OF LAMEA SMART INHALERS, BY INDICATION, 2020-2030 ($MILLION)
- TABLE 79.REST OF LAMEA SMART INHALERS, BY END USER, 2020-2030 ($MILLION)
- TABLE 80.ADHERIUM LIMITED: KEY EXECUTIVES
- TABLE 81.ADHERIUM LIMITED: COMPANY SNAPSHOT
- TABLE 82.ADHERIUM LIMITED: OPERATING SEGMENTS
- TABLE 83.ADHERIUM LIMITED: PRODUCT PORTFOLIO
- TABLE 84.ADHERIUM LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 85.APTAR GROUP INC.(COHERO HEALTH INC.): KEY EXECUTIVES
- TABLE 86.APTAR GROUP INC.(COHERO HEALTH INC.): COMPANY SNAPSHOT
- TABLE 87.APTAR GROUP INC.(COHERO HEALTH INC.): OPERATING SEGMENTS
- TABLE 88.APTAR GROUP INC.(COHERO HEALTH INC.): PRODUCT PORTFOLIO
- TABLE 89.APTAR GROUP INC.(COHERO HEALTH INC.): KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 90.ASTRAZENECA, INC.: KEY EXECUTIVES
- TABLE 91.ASTRAZENECA, INC.: COMPANY SNAPSHOT
- TABLE 92.ASTRAZENECA, INC.: OPERATING SEGMENTS
- TABLE 93.ASTRAZENECA, INC.: PRODUCT PORTFOLIO
- TABLE 94.ASTRAZENECA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 95.COGNITA LABS, LLC: KEY EXECUTIVES
- TABLE 96.COGNITA LABS, LLC: COMPANY SNAPSHOT
- TABLE 97.COGNITA LABS, LLC: OPERATING SEGMENTS
- TABLE 98.COGNITA LABS, LLC: PRODUCT PORTFOLIO
- TABLE 99.COGNITA LABS, LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 100.GLAXOSMITHKLINE PLC: KEY EXECUTIVES
- TABLE 101.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
- TABLE 102.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
- TABLE 103.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
- TABLE 104.NOVARTIS AG: KEY EXECUTIVES
- TABLE 105.NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 106.NOVARTIS AG: OPERATING SEGMENTS
- TABLE 107.NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 108.NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 109.OPKO HEALTH INC.: KEY EXECUTIVES
- TABLE 110.OPKO HEALTH INC.: COMPANY SNAPSHOT
- TABLE 111.OPKO HEALTH INC.: OPERATING SEGMENTS
- TABLE 112.OPKO HEALTH INC.: PRODUCT PORTFOLIO
- TABLE 113.PHILIP MORRIS INTERNATIONAL INC. (VECTURA GROUP PLC): KEY EXECUTIVES
- TABLE 114.PHILIP MORRIS INTERNATIONAL INC. (VECTURA GROUP PLC): COMPANY SNAPSHOT
- TABLE 115.PHILIP MORRIS INTERNATIONAL INC. (VECTURA GROUP PLC): OPERATING SEGMENTS
- TABLE 116.PHILIP MORRIS INTERNATIONAL INC. (VECTURA GROUP PLC): PRODUCT PORTFOLIO
- TABLE 117.PHILIP MORRIS INTERNATIONAL INC. (VECTURA GROUP PLC): KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 118.RESMED INC. (PROPELLER HEALTH): KEY EXECUTIVES
- TABLE 119.RESMED INC. (PROPELLER HEALTH): COMPANY SNAPSHOT
- TABLE 120.RESMED INC. (PROPELLER HEALTH): OPERATING SEGMENTS
- TABLE 121.RESMED INC. (PROPELLER HEALTH): PRODUCT PORTFOLIO
- TABLE 122.RESMED INC. (PROPELLER HEALTH): KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 123.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 124.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 125.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
- TABLE 126.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 127.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- LIST OF FIGURES
- FIGURE 1.GLOBAL SMART INHALERS MARKET SEGMENTATION
- FIGURE 2.GLOBAL SMART INHALERS MARKET
- FIGURE 3.SEGMENTATION SMART INHALERS MARKET
- FIGURE 4.TOP INVESTMENT POCKET IN SMART INHALERS MARKET
- FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
- FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
- FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
- FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
- FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
- FIGURE 11.LOW THREAT OF SUBSTITUTION
- FIGURE 12.HIGH COMPETITIVE RIVALRY
- FIGURE 13.TOP PLAYER POSITIONING, 2020
- FIGURE 14.MARKET SHARE ANALYSIS, 2020
- FIGURE 15.RESTRAINTS AND DRIVERS: SMART INHALERS MARKET
- FIGURE 16.SMART INHALERS MARKET SEGMENTATION, BY PRODUCT
- FIGURE 17.SMART INHALERS MARKET FOR INHALERS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 18.SMART INHALERS MARKET FOR NEBULIZERS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 19.SMART INHALERS MARKET SEGMENTATION, BY INDICATION
- FIGURE 20.SMART INHALERS MARKET FOR ASTHMA, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 21.SMART INHALERS MARKET FOR COPD, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 22.SMART INHALERS MARKET SEGMENTATION, BY END USER
- FIGURE 23.SMART INHALERS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 24.SMART INHALERS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 25.ADHERIUM LIMITED: NET SALES, 2018-2020 ($MILLION)
- FIGURE 26.ADHERIUM LIMITED: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 27.ADHERIUM LIMITED: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 28.APTAR GROUP INC.(COHERO HEALTH INC.): NET SALES, 2018-2020 ($MILLION)
- FIGURE 29.APTAR GROUP INC.(COHERO HEALTH INC.): REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 30.APTAR GROUP INC.(COHERO HEALTH INC.): REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 31.ASTRAZENECA, INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 32.ASTRAZENECA, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 33.ASTRAZENECA, INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 34.GLAXOSMITHKLINE PLC: NET SALES, 2018-2020 ($MILLION)
- FIGURE 35.GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 36.GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 37.NOVARTIS AG: NET SALES, 2018-2020 ($MILLION)
- FIGURE 38.NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 39.NOVARTIS AG: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 40.OPKO HEALTH INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 41.OPKO HEALTH INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 42.OPKO HEALTH INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 43.PHILIP MORRIS INTERNATIONAL INC. (VECTURA GROUP PLC): NET SALES, 2018-2020 ($MILLION)
- FIGURE 44.PHILIP MORRIS INTERNATIONAL INC. (VECTURA GROUP PLC): REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 45.PHILIP MORRIS INTERNATIONAL INC. (VECTURA GROUP PLC): REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 46.RESMED INC. (PROPELLER HEALTH): NET SALES, 2018-2020 ($MILLION)
- FIGURE 47.RESMED INC. (PROPELLER HEALTH): REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 48.RESMED INC. (PROPELLER HEALTH): REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 49.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 50.TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 51.TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2020 (%)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook